LY2109761

Catalog No. A11133

LY2109761, a novel transforming growth factor β receptor type I and type II dual inhibitor, as a therapeutic approach to suppressing pancreatic cancer metastasis
  • Uto T, .et al. Critical role of plasmacytoid dendritic cells in induction of oral tolerance, J Allergy Clin Immunol, 2018, Jun;141(6):2156-2167.e9 PMID: 29477579
  • Jared M. Fischer, .et al. Single cell lineage tracing reveals a role for TgfβR2 in intestinal stem cell dynamics and differentiation, Proc Natl Acad Sci U S A, 2016, Oct 25; 113(43): 12192-12197 PMID: 27791005
Catalog Num A11133
M. Wt 441.5
Formula C26H27N5O2
Purity >98%
Storage at -20°C 3 years Powder
CAS No. 700874-71-1
Synonyms LY-2109761
SMILES C1CC2=C(C(=NN2C1)C3=CC=CC=N3)C4=C5C=CC(=CC5=NC=C4)OCCN6CCOCC6
LY2109761, a novel transforming growth factor β receptor type I and type II dual inhibitor, as a therapeutic approach to suppressing pancreatic cancer metastasis
In vitro (25°C) DMSO 2 mg/mL (4.52 mM)
Water <1 mg/mL (<1 mM)
Ethanol <1 mg/mL (<1 mM)
In vivo 0.5% CMC/0.25% Tween 80 16 mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Adooq tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
0.1 mM 22.65 mL 113.25 mL 226.5 mL
0.5 mM 4.53 mL 22.65 mL 45.3 mL
1 mM 2.27 mL 11.33 mL 22.65 mL
5 mM 0.45 mL 2.27 mL 4.53 mL

*The above data is based on the productmolecular weight 441.5 . Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.